Actively Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-02-12
230
Participants Needed
24
Research Sites
80 weeks
Total Duration
On this page
Sponsors
N
Nanjing Leads Biolabs Co.,Ltd
Lead Sponsor
S
Sun Yat-sen University
Collaborating Sponsor
AI-Summary
What this Trial Is About
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
CONDITIONS
Official Title
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Agree to follow the trial treatment plan and visit schedule, and voluntarily sign informed consent
- Aged between 18 and 75 years at the time of consent
- Physical status score of 0 to 1 on the Eastern Cooperative Oncology Group scale
- Expected survival time of at least 12 weeks
- At least one measurable tumor lesion according to RECIST 1.1 criteria
- Adequate organ and bone marrow function based on lab tests
- Willingness to use effective contraception during the study and for 6 months after, with a negative pregnancy test for women of childbearing age within 7 days before first dose
You will not qualify if you...
- Participation in other antineoplastic drug trials within 4 weeks before starting study drug
- Expected to receive other systemic or local anti-tumor therapy outside this study during participation
- Use of immunomodulatory drugs within 2 weeks before starting study drug
- Active infection at the time of screening
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage or intervention
- History of immunodeficiency including HIV positive status
- Active hepatitis B or C infection
- Pregnant or breastfeeding women
- History of mental illness impairing consent, drug abuse, alcoholism, or addiction
- Any other condition that may affect compliance or suitability as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230031
Actively Recruiting
2
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
3
Beijing Chest Hospital，Capital Medical University
Beijing, Beijing Municipality, China, 101100
Actively Recruiting
4
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
5
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361102
Actively Recruiting
6
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
7
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China, 510062
Actively Recruiting
8
Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China, 541001
Actively Recruiting
9
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530021
Actively Recruiting
10
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150081
Actively Recruiting
11
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China, 471023
Actively Recruiting
12
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
13
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
Actively Recruiting
14
Xiangyang Central Hospital
Xiangyang, Hubei, China, 441106
Actively Recruiting
15
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China, 410011
Not Yet Recruiting
16
Ganzhou People's Hospital
Ganzhou, Jiangxi, China, 341006
Actively Recruiting
17
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China, 330029
Actively Recruiting
18
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, China, 110167
Actively Recruiting
19
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
20
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China, 030012
Actively Recruiting
21
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China, 610072
Actively Recruiting
22
Mianyang Central Hospital
Mianyang, Sichuan, China, 621000
Actively Recruiting
23
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
24
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China, 317000
Actively Recruiting
Research Team
L
li Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here